Thienopyridines in percutaneous coronary interventions: standard procedures and high risk subsets

Area of Science:

• Interventional Cardiology
• Cardiovascular Research
• Pharmacology

Background:

• Subacute stent thrombosis poses significant clinical and economic challenges.
• Increasing use of complex devices like drug-eluting stents necessitates optimized antiplatelet strategies.
• Current guidelines require clarification regarding antiplatelet therapy duration and specific patient populations.

Purpose of the Study:

• To review the pathophysiology of stent thrombosis.
• To discuss critical issues surrounding thienopyridine use in coronary interventions.
• To address clinical scenarios not fully covered by existing guidelines, such as anticoagulated patients.

Main Methods:

• Literature review focusing on interventional cardiology, stent thrombosis, and antiplatelet therapy.
• Analysis of current recommendations and guidelines.
• Discussion of complex clinical scenarios and emerging evidence.

Main Results:

• Stent thrombosis remains a concern, particularly with advanced stenting techniques.
• Optimal initiation and duration of dual antiplatelet therapy (aspirin plus a thienopyridine) are debated.
• Evidence gaps exist for specific patient groups, including those on chronic anticoagulation.

Conclusions:

• A comprehensive understanding of stent thrombosis pathophysiology is essential.
• Evidence-based decisions on thienopyridine use are critical for patient outcomes.
• Further research and guideline refinement are needed for anticoagulated patients undergoing coronary interventions.